| Name | AP20187 |
| Description | AP20187 (B/B Homodimerizer) is a cell-permeable compound used to dimerize FK506-binding protein (FKBP) fusion proteins, thereby initiating biological signaling cascades, gene expression, or disrupting protein-protein interactions. |
| In vitro | Treatment of LNCaP cells with AP20187 (B/B Homodimerizer) at a concentration of 100 nM significantly reduces ro-iCaspase-9 levels, while the smaller, processed, active form of caspase-9 becomes evident. |
| In vivo | Treatment with AP20187 significantly mitigates the effects of experimental autoimmune encephalomyelitis (EAE) on myelin sheaths in mice, markedly decreasing the prevalence of deteriorating axons and enhancing axonal density within demyelination sites in the lumbar spinal cord of PLP/Fv2E-PERK mice. Additionally, real-time PCR analysis reveals that AP20187 (B/B Homodimerizer) administration at doses of 0.5 mg/kg, 2 mg/kg, or 5 mg/kg notably elevates CHOP mRNA levels in the central nervous system (CNS) of PLP/Fv2E-PERK mice at post-infection day (PID) 12. |
| Storage | store at low temperature,keep away from direct sunlight | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 50 mg/mL (33.72 mM), Sonication is recommended.
Ethanol : 130 mg/mL (87.67 mM), Sonication is recommended.
10% DMSO+40% PEG300+5% Tween 80+45% Saline : 2 mg/mL (1.35 mM), Sonication is recommended.
|
| Keywords | Inhibitor | inhibit | FKBP homodimerizer | FKBP | FK506-binding protein | AP-20187 | AP20187 | AP 20187 |
| Inhibitors Related | Everolimus | Ascomycin | Shield-1 | Rimiducid | Tacrolimus monohydrate | ElteN378 | Etonogestrel | GPI-1046 | SAFit2 | GPI-1485 | FKBP12 PROTAC dTAG-13 | Rapamycin |
| Related Compound Libraries | Bioactive Compound Library | NO PAINS Compound Library | PPI Inhibitor Library | Immunology/Inflammation Compound Library | Bioactive Compounds Library Max | Human Metabolite Library |
United States
